Hepion Pharmaceuticals Regains Compliance with Nasdaq Listing Requirements
September 03 2019 - 4:30PM
Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a biopharmaceutical
company focused on the development of therapeutic drugs for the
treatment of liver disease arising from non-alcoholic
steatohepatitis (“NASH”) and chronic viral infection, today
announced that it has received notification from the Nasdaq
Hearings Panel (the “Panel”) that it has regained compliance with
Nasdaq’s minimum shareholders’ equity rule, and is in compliance
with other applicable requirements as set forth in the Panel’s
decision dated May 3, 2019 and required for listing on The Nasdaq
Stock Market. The Company's shares will continue to be traded on
The Nasdaq Stock Market under the symbol HEPA.
About Hepion Pharmaceuticals
Hepion Pharmaceuticals is a clinical stage
biopharmaceutical company focused on the development of targeted
therapies for liver disease arising from non-alcoholic
steatohepatitis (NASH) and chronic hepatitis virus infection (HBV,
HCV, HDV). The Company’s lead drug candidate, CRV431, reduces liver
fibrosis and hepatocellular carcinoma tumor burden in experimental
models of NASH. Preclinical studies also have demonstrated
antiviral activities towards HBV, HCV, and HDV through several
mechanisms. These diverse therapeutic activities result from
CRV431’s potent inhibition of cyclophilins, which are involved in
many disease processes. Currently in clinical phase development,
CRV431 shows potential to play an important role in the overall
treatment of liver disease - from triggering events through to
end-stage disease.
Forward Looking Statements
Certain statements in this press release are
forward-looking within the meaning of the Private Securities
Litigation Reform Act of 1995. These statements may be
identified by the use of forward-looking words such as
“anticipate,” “believe,” “forecast,” “estimated,” and “intend,”
among others. These forward-looking statements are based on Hepion
Pharmaceuticals’ current expectations and actual results could
differ materially. There are a number of factors that could
cause actual events to differ materially from those indicated by
such forward-looking statements. These factors include, but are not
limited to, substantial competition; our ability to continue as a
going concern; our need for additional financing; uncertainties of
patent protection and litigation; uncertainties with respect to
lengthy and expensive clinical trials, that results of earlier
studies and trials may not be predictive of future trial results;
uncertainties of government or third party payer reimbursement;
limited sales and marketing efforts and dependence upon third
parties; and risks related to failure to obtain FDA clearances or
approvals and noncompliance with FDA regulations. As with any drug
candidates under development, there are significant risks in the
development, regulatory approval, and commercialization of new
products. There are no guarantees that future clinical trials
discussed in this press release will be completed or successful, or
that any product will receive regulatory approval for any
indication or prove to be commercially successful. Hepion
Pharmaceuticals does not undertake an obligation to update or
revise any forward-looking statement. Investors should read the
risk factors set forth in Hepion Pharmaceuticals’ Form 10-K for the
year ended December 31, 2018 and other periodic reports filed with
the Securities and Exchange Commission.
For further information, please contact:
Stephen KilmerHepion Pharmaceuticals Investor RelationsDirect:
(646) 274-3580skilmer@hepionpharma.com
Hepion Pharmaceuticals (NASDAQ:HEPA)
Historical Stock Chart
From Aug 2024 to Sep 2024
Hepion Pharmaceuticals (NASDAQ:HEPA)
Historical Stock Chart
From Sep 2023 to Sep 2024